QC
BMY icon

Quantessence Capital’s Bristol-Myers Squibb BMY Stock Holding History

Quantessence Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,119
Closed -$553K – 84
2026
Q1 		$553K Buy
+9,119
New +$532K 2.69% 11
2025
Q2 		– Sell
-37,100
Closed -$2.26M – 213
2025
Q1 		$2.26M Buy
+37,100
New +$2.16M 0.57% 35

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Quantessence Capital's BMY Position: Q2 2026 in Review

Quantessence Capital sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 9,119 shares — an estimated $553K sold.

Quantessence Capital first reported a position in BMY in Q1 2025 and held it in 2 quarters. The position peaked at $2.26M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Quantessence Capital reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
  • Quantessence Capital sold 9,119 Bristol-Myers Squibb shares in Q2 2026, an estimated $553K.
  • Quantessence Capital first reported a position in Bristol-Myers Squibb in Q1 2025 and held it in 2 quarters.
  • Quantessence Capital's Bristol-Myers Squibb position peaked at $2.26M in Q1 2025.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Quantessence Capital's 13F filing for Q2 2026, filed 14 Aug 2026.